Skip to main content
Caplight Logo









ENA Respiratory

ENA Respiratory

Private
MelbourneHealthcare & Life Scienceshttps://enarespiratory.com/

Last Round

Series B

Oct 22, 2025

Total Funding Raised

$46.83M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defence enhancers to combat respiratory viral infections by boosting the body's local innate immune response.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

innate immune boosterantiviral nasal sprayprophylactic therapyTLR2/6 agonistrespiratory virus preventionclinical-stage biotechinnate immunitynasal dry powdervirus-agnostic therapyimmune primingpandemic preparednessbiopharmadrug developmentimmune health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ENA Respiratory Comparables

Compare ENA Respiratory with similar companies based on industry and business-model similarity.

ENA Respiratory comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NorthLinks Bio
85%
Leyden Labs
79%
SaNOtize Research & Development Corp.
77%

ENA Respiratory Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 22, 2025
GrantSep 5, 2024
GrantAug 29, 2023
GrantJan 9, 2023
VC RoundJun 15, 2021
Series A Extension
Sep 28, 2020

Key People

Founding team and executive leadership

Christophe Demaison

Managing Director and CEO

Executive Team

ENA Respiratory Investors

Notable investors and investment history

ENA Respiratory investors
InvestorRounds
Flu LabSeries B
Minderoo FoundationVC Round
United States Department of DefenseGrant
Hostplus Superannuation FundSeries A Extension
Bill & Melinda Gates FoundationSeries B
UniseedSeries A, Series A Extension, Series B, VC Round
Stoic Venture CapitalSeries A Extension, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 41% MoM.

  • Jun 1, 2025

    Monthly visitors grew 100% MoM, reaching 1.6K.

ENA Respiratory Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ENA Respiratory Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ENA Respiratory's valuation, stock price, and market status.

Firmographic Details

HeadquartersMelbourne
Employee Range4
Year Founded2014
Last FundingOct 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?